Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $39M | $14M | $11M | $14M | 9.5% | -5.8% | -18.7% |
| 2024 | $41M | $16M | $14M | $15M | 11.8% | -18.6% | -16.6% |
| 2023 | $50M | $23M | $17M | $22M | 13.0% | -3.9% | 1.0% |
| 2022 | $52M | $27M | $16M | $20M | 14.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 52.28 | 50.22 | 40.90 | 38.52 |
| Operating Revenue | - | 52.28 | 50.22 | 40.90 | 38.52 |
| Cost Of Revenue | - | 20.08 | 20.19 | 16.76 | 16.52 |
| Gross Profit | - | 32.20 | 30.04 | 24.14 | 22 |
| Operating Expense | - | 12.41 | 13.26 | 10.55 | 10.60 |
| Research And Development | - | 0.49 | 0.56 | 0.81 | 0.67 |
| Selling General And Administration | - | 11.91 | 12.70 | 9.74 | 9.93 |
| Total Expenses | - | 32.49 | 33.45 | 27.31 | 27.12 |
| Operating Income | - | 19.79 | 16.78 | 13.59 | 11.40 |
| Total Operating Income As Reported | - | 19.79 | 16.78 | 13.59 | 11.40 |
| EBITDA | - | 26.87 | 23.14 | 16.44 | 14.41 |
| Normalized EBITDA | - | 26.21 | 20.11 | 13.07 | 11.60 |
| EBIT | - | 19.79 | 16.78 | 13.59 | 11.40 |
| Other Non Operating Income Expenses | - | 0.21 | 0.28 | -0.16 | -0.10 |
| Other Income Expense | - | 0.87 | 3.31 | 3.21 | 2.71 |
| Pretax Income | - | 20.66 | 20.09 | 16.80 | 14.11 |
| Tax Provision | - | 4.19 | 3.45 | 2.93 | 2.82 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.13 | 0.52 | 0.59 | 0.56 |
| Net Income Continuous Operations | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income From Continuing And Discontinued Operation | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income From Continuing Operation Net Minority Interest | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income Common Stockholders | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income Including Noncontrolling Interests | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Normalized Income | - | 15.95 | 14.12 | 11.09 | 9.04 |
| Diluted NI Availto Com Stockholders | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Basic Average Shares | - | 3.63 | 3.63 | 3.34 | 3.19 |
| Diluted Average Shares | - | 3.64 | 3.64 | 3.50 | 3.24 |
| Reconciled Depreciation | - | 7.08 | 6.37 | 2.85 | 3.01 |
| Reconciled Cost Of Revenue | - | 20.08 | 20.19 | 16.76 | 16.52 |
| Total Unusual Items | - | 0.66 | 3.04 | 3.37 | 2.81 |
| Total Unusual Items Excluding Goodwill | - | 0.66 | 3.04 | 3.37 | 2.81 |
| Gain On Sale Of Security | - | 0.66 | 3.04 | 3.37 | 2.81 |
| General And Administrative Expense | - | 10.41 | 11.02 | 7.84 | 7.88 |
| Other Gand A | - | 10.41 | 11.02 | 7.84 | 7.88 |
| Selling And Marketing Expense | - | 1.51 | 1.68 | 1.90 | 2.05 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Utah Medical Products, Inc.this co. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Fulcrum Therapeutics, Inc. | FULC | $225M | - | 0.64 | -21.5% | - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR |
| - |
| - |
| - |
| - |
| - |
| - |
| $219M |
| -1.83 |
| 1.12 |
| -61.1% |
| -1.49 |
| Pro-Dex, Inc. | PDEX | $214M | 23.83 | 5.84 | 24.5% | 16.29 |
| Keros Therapeutics, Inc. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| RxSight, Inc. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Atrium Therapeutics, Inc. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Peer Median | - | -2.74 | 0.89 | -17.8% | -1.49 | |
Historically, Nov has averaged the highest return (+4.1%); Apr the lowest (-3.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +9.1%Positive MonthJan 2026: +9.11% | +9.1%Positive MonthFeb 2026: +9.09% | -6.9%Negative MonthMar 2026: -6.94% | +5.5%Positive MonthApr 2026: +5.53% | +1.6%Neutral MonthMay 2026: +1.57% | +3.8%Positive MonthJun 2026: +3.81% | +2.2%Positive MonthJul 2026: +2.23% | +2.3%*Positive MonthAug 2026: +2.27% | — | — | — | — |
| 2025 | -0.4%Neutral MonthJan 2025: -0.39% | -2.6%Negative MonthFeb 2025: -2.65% | -6.0%Negative MonthMar 2025: -5.99% | -7.7%Negative MonthApr 2025: -7.66% | +6.4%Positive MonthMay 2025: +6.43% | +3.3%Positive MonthJun 2025: +3.34% | -2.3%Negative MonthJul 2025: -2.32% | +11.9%Positive MonthAug 2025: +11.89% | +1.2%Neutral MonthSep 2025: +1.22% | -7.7%Negative MonthOct 2025: -7.73% | -3.0%Negative MonthNov 2025: -3.01% | -0.7%Neutral MonthDec 2025: -0.69% |
| 2024 | -5.9%Negative MonthJan 2024: -5.95% | -11.4%Negative MonthFeb 2024: -11.40% | +1.3%Neutral MonthMar 2024: +1.33% | -6.9%Negative MonthApr 2024: -6.90% | +3.2%Positive MonthMay 2024: +3.16% | -2.2%Negative MonthJun 2024: -2.17% | +4.2%Positive MonthJul 2024: +4.18% | -2.3%Negative MonthAug 2024: -2.31% | -1.6%Neutral MonthSep 2024: -1.59% | -5.3%Negative MonthOct 2024: -5.28% | +3.0%Positive MonthNov 2024: +2.95% | -5.8%Negative MonthDec 2024: -5.79% |
| 2023 | -8.4%Negative MonthJan 2023: -8.36% | -0.4%Neutral MonthFeb 2023: -0.38% | +3.3%Positive MonthMar 2023: +3.26% | +0.1%Neutral MonthApr 2023: +0.07% | -1.4%Neutral MonthMay 2023: -1.42% | -0.3%Neutral MonthJun 2023: -0.31% | +5.5%Positive MonthJul 2023: +5.50% | -6.8%Negative MonthAug 2023: -6.84% | -6.1%Negative MonthSep 2023: -6.11% | -7.5%Negative MonthOct 2023: -7.53% | +6.0%Positive MonthNov 2023: +6.01% | -0.1%Neutral MonthDec 2023: -0.09% |
| 2022 | -5.9%Negative MonthJan 2022: -5.93% | -4.3%Negative MonthFeb 2022: -4.32% | -0.2%Neutral MonthMar 2022: -0.17% | -5.9%Negative MonthApr 2022: -5.86% | +1.8%Neutral MonthMay 2022: +1.83% | -0.3%Neutral MonthJun 2022: -0.28% | +6.3%Positive MonthJul 2022: +6.33% | +0.6%Neutral MonthAug 2022: +0.61% | -7.2%Negative MonthSep 2022: -7.17% | +5.0%Positive MonthOct 2022: +4.97% | -0.5%Neutral MonthNov 2022: -0.55% | +12.9%Positive MonthDec 2022: +12.88% |
| 2021 | — | — | — | — | -1.8%Neutral MonthMay 2021: -1.78% | -0.8%Neutral MonthJun 2021: -0.78% | +5.1%Positive MonthJul 2021: +5.13% | -0.9%Neutral MonthAug 2021: -0.89% | +4.8%Positive MonthSep 2021: +4.79% | +4.3%Positive MonthOct 2021: +4.30% | +15.2%Positive MonthNov 2021: +15.21% | -10.4%Negative MonthDec 2021: -10.36% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
